Analysts Are Bullish on Vericel Stock in September



Vericel business trends

Vericel (VCEL) is a biopharmaceutical company focused on the use of cell therapies to target the underserved opportunity in the burn care and sports medicines markets. The FDA noted that in December 2016, the company secured FDA approval for MACI, a cartilage repair product, to treat symptomatic and full-thickness cartilage defects of the knees.

The company has another FDA-approved product, Epicel, in its portfolio. According to Vericel’s September investor presentation, Epicel is used for permanent skin replacement in patients suffering from severe burns.

In the second quarter, Vericel (VCEL) reported revenues of $19.01 million, which is a year-over-year increase of 12.1%. These revenues surpassed the consensus estimate by $0.38 million.

Article continues below advertisement

The company also reported EPS of -$0.12 in the second quarter. Vericel also witnessed a 34.0% year-over-year increase in revenues in the first half of the year, driven by strong adoption of MACI and Epicel. The chart above highlights the overall revenue growth trajectory of Vericel after the addition of MACI and Epicel to its portfolio.

Target price

The 12-month consensus analyst recommendation for Vericel on September 25 is a “strong buy.” The 12-month consensus target price for the company is $15.62, which is 6.99% higher than its closing price on September 25. The highest target price estimate for the company is $17.00, and the lowest target price estimate is $14.00.

Of the five analysts covering Vericel in September, three analysts recommended the company as a “strong buy,” and two analysts recommended the company as a “buy.”

Vericel has reported year-to-date returns of 167.89%. The company also reported returns of 8.96%, 16.8%, and 41.06%, respectively, in the last week, the last month, and the last quarter. It reported returns of 50.52% and 201.03%, respectively, in the last half year and the last year.

Vericel closed at $14.60 on September 25, which was 342.42% higher than the company’s 52-week low of $3.30 and 1.35% lower than the company’s 52-week high of $14.80.


More From Market Realist